trending Market Intelligence /marketintelligence/en/news-insights/trending/lnCbS3Re1a2znvY5UrXrsQ2 content esgSubNav
In This List

Exelixis gets FDA expanded approval for kidney cancer drug

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


Exelixis gets FDA expanded approval for kidney cancer drug

The U.S. Food and Drug Administration approved Exelixis Inc.'s Cabometyx tablets for the expanded indication of patients with advanced renal cell carcinoma.

Renal cell carcinoma is the most common form of kidney cancer in adults.

The expanded approval of the drug is based on results from a phase 2 trial in patients with previously untreated renal cell carcinoma, where the drug showed statistically significant and clinically meaningful improvement in progression-free survival versus current standard of care sunitinib.

Cabometyx, which the agency approved in April 2016 to treat advanced renal cell carcinoma in patients who have received prior anti-angiogenic therapy, demonstrated a 52% reduction in the rate of disease progression or death in the trial. Median progression-free survival for the drug was 8.6 months versus 5.3 months for sunitinib.

The FDA has previously granted priority review to the company's supplemental new drug application for Cabometyx.